Brief: Infant Bacterial Therapeutics Updates On Phase III Study Of IBP-9414
Sept 2 (Reuters) - Infant Bacterial Therapeutics AB
(publ) IBTb.ST :
* SAID ON FRIDAY PHASE III STUDY OF IBP-9414, BACTERIAL
STRAIN
FOUND NATURALLY IN HUMAN BREAST MILK, SHOWS NO SIGNIFICANT
EFFECTS ON PRIMARY ENDPOINTS
* BUT STUDY SHOWS SIGNIFICANT REDUCTION IN SECONDARY
ENDPOINT,
ALL-CAUSE MORTALITY
Source text for Workspace: urn:newsml:reuters.com:*:nMFN7P92s4
Further company coverage: IBTb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Infant Bacterial Therapeutics AB
See all newsBrief: Infant Bacterial Therapeutics Gets FDA Request For Type B Pre-BLA Meeting
Brief: Infant Bacterial Therapeutics Q2 Operating Loss Widens To SEK 30.1 Mln
Brief: Infant Bacterial Therapeutics CFO Leaves The Company
Brief: Infant Bacterial Announces Phase III IBP-9414 Study Results
Brief: Infant Bacterial Therapeutics Q4 Operating Loss SEK 20.5 Mln